Copyright
©The Author(s) 2015.
World J Crit Care Med. Aug 4, 2015; 4(3): 230-239
Published online Aug 4, 2015. doi: 10.5492/wjccm.v4.i3.230
Published online Aug 4, 2015. doi: 10.5492/wjccm.v4.i3.230
Patients | PV n = 323 | ET n = 625 | ||
JAK2V617 mutation status | Hetero homozygous hetero wild type | |||
No. of patients | 219 | 104 | 368 | 237 |
At diagnosis | ||||
Major arterial events | 21% | 15.4% | 21.7% | 10.5% |
Venous events | 2.9% | 2.9% | 7.9% | 4.7% |
During 10 yr follow-up (not on aspirin) | ||||
Major arterial events | 10.1% | 12.5% | 6.3% | 5.8% |
Venous events | 4.1% | 7.7% | 6.3% | 2.7% |
Total during life time follow-up | ||||
Major arterial | 31.1% | 27.9% | 28% | 16.3% |
Venous | 10.5% | 10.6% | 14.2% | 7.4% |
- Citation: Michiels JJ. Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients. World J Crit Care Med 2015; 4(3): 230-239
- URL: https://www.wjgnet.com/2220-3141/full/v4/i3/230.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v4.i3.230